| Dr Alex Velasco Delrosario, MD | |
|
5440 West Sahara, Ste 202, Las Vegas, NV 89146 | |
| (702) 380-8200 | |
| (702) 380-3220 |
| Full Name | Dr Alex Velasco Delrosario |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 37 Years |
| Location | 5440 West Sahara, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336248145 | NPI | - | NPPES |
| 002018859 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 10057 (Nevada) | Primary |
| Entity Name | State Of Nevada |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760572010 PECOS PAC ID: 9234022153 Enrollment ID: O20040212000160 |
News Archive
Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.
Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.
Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).
Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.
Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.
› Verified 2 days ago
| Entity Name | Alex Del Rosario Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376836080 PECOS PAC ID: 2466623715 Enrollment ID: O20110919000581 |
News Archive
Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.
Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.
Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).
Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.
Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alex Velasco Delrosario, MD 5440 West Sahara, Ste 202, Las Vegas, NV 89146 Ph: (702) 380-8200 | Dr Alex Velasco Delrosario, MD 5440 West Sahara, Ste 202, Las Vegas, NV 89146 Ph: (702) 380-8200 |
News Archive
Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease.
Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.
Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).
Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.
Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.
› Verified 2 days ago
Dr. Ejine Okoroafor, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5440 W Sahara Ave, Suite 202, Las Vegas, NV 89146 Phone: 914-426-7774 | |
Dr. Garet Jefferson Zaugg, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2020 Wellness Way Ste 300, Las Vegas, NV 89106 Phone: 702-432-2233 Fax: 702-800-5456 | |
Dr. Muhammed A Hyder, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2465 E Twain Ave, Las Vegas, NV 89121 Phone: 702-789-6201 Fax: 304-522-0686 | |
Dr. Krista Linn Pinard, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3016 W Charleston Blvd Ste 150, Las Vegas, NV 89102 Phone: 702-790-2701 | |
Gobinder S. Chopra, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 6410 Medical Center St Ste A100, Las Vegas, NV 89148 Phone: 702-796-8500 Fax: 702-796-8502 | |
Eden Santiago Lee, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3014 W Charleston Blvd Ste 130, Las Vegas, NV 89102 Phone: 702-671-6475 Fax: 702-671-6440 | |
John Reitano, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 S Rancho Dr, Ste I62, Las Vegas, NV 89106 Phone: 702-897-7250 Fax: 702-706-4838 |